Celgene Corporation announced the results of a post-hoc analysis of data from the Phase 3 RADIANCE Part B trial showing that ozanimod reduced cortical grey matter volume loss versus first-line treatment, Avonex, in adults with relapsing multiple sclerosis across all age groups, including patients ages 18 to 25. The analysis will be presented at the 2019 American Academy of Neurology Annual Meeting in Philadelphia, May 4-10, 2019. RADIANCE evaluated two doses of oral ozanimod compared with interferon beta-1a in 1,313 patients with RMS between the ages of 18 and 55 years old. In this post-hoc analysis of 874 patients, treatment effect on serial brain volume, including thalamic volume and cortical grey matter, was evaluated by patient age at baseline, 12 months and 24 months. Patients in the 18 to 25 age group tended to have greater brain volume at baseline but more active disease as measured by gadolinium-enhancing MRI lesions. There was also a trend for this age group to experience greater whole brain volume loss at both 12 and 24 months compared with the older groups. Patients across all age groups treated with ozanimod lost less cortical grey matter volume than did those treated with interferon beta-1a over 24 months, including patients in the 18 to 25 age group. In the RADIANCE Part B trial, the most common adverse reactions that were higher with ozanimod than with interferon beta-1a were upper respiratory tract infections, urinary tract infections, increases of alanine aminotransferase and increases of gamma-glutamyl transferase.
